NCT01827280View on ClinicalTrials.gov

Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

November 30, 2016

Conditions
1- Microvascular Function2-oxidative Stress3-inflammation
Interventions
DRUG

Vildagliptin

Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.

Trial Locations (1)

20550-900

Laboratory for Clinical and Experimental Research on Vascular Biology, Rio de Janeiro

All Listed Sponsors
collaborator

Laboratory for Clinical and Experimental Research on Vascular Biology

UNKNOWN

lead

Rio de Janeiro State University

OTHER

NCT01827280 - Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women | Biotech Hunter | Biotech Hunter